Table 3.
Comparison | Costs (€) | Costs 1st-line (€) | LYs | QALYs | Δ Costs (€) | Δ Effects | ICER (€) |
---|---|---|---|---|---|---|---|
Gefitinib | 65,889 | 39,467 | 2.01 | 1.36 | – | – | – |
Erlotinib | 64,035 | 39,825 | 2.04 | 1.39 | Dominates gefitinib | ||
Afatinib | 69,418 | 42,416 | 2.24 | 1.52 | 5383 | 0.13 | 41,504 |
Osimertinib | 131,997 | 124,149 | 2.92 | 2.01 | 62,579 | 0.49 | 128,343 |
ICER incremental cost-effectiveness ratio, LYs life-years, QALYs quality-adjusted life-years, Δ difference in costs/effects